Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. ICORG 10-01, V5

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Cancer Trials Ireland
ClinicalTrials.gov Identifier:
NCT01566747
First received: March 8, 2012
Last updated: June 27, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)